116 related articles for article (PubMed ID: 35398619)
1. Relationship between the changes of positivity rate of HER2 expression and the diameter of invasive lesions in early breast cancer and its clinical significance.
Han D; Shen R; Yue M; Zhao M; Yu Y; Yao J; Liu Y
Pathol Res Pract; 2022 May; 233():153877. PubMed ID: 35398619
[TBL] [Abstract][Full Text] [Related]
2. Possible Prognostic Role of HER2/Neu in Ductal Carcinoma In Situ and Atypical Ductal Proliferative Lesions of the Breast.
Daoud SA; Ismail WM; Abdelhamid MS; Nabil TM; Daoud SA
Asian Pac J Cancer Prev; 2016; 17(8):3733-6. PubMed ID: 27644608
[TBL] [Abstract][Full Text] [Related]
3. The prognostic role of HER2 expression in ductal breast carcinoma in situ (DCIS); a population-based cohort study.
Borgquist S; Zhou W; Jirström K; Amini RM; Sollie T; Sørlie T; Blomqvist C; Butt S; Wärnberg F
BMC Cancer; 2015 Jun; 15():468. PubMed ID: 26062614
[TBL] [Abstract][Full Text] [Related]
4. Significance of HER2 in Microinvasive Breast Carcinoma.
Zhang H; Moisini I; Turner BM; Wang X; Dhakal A; Yang Q; Kovar S; Schiffhauer LM; Hicks DG
Am J Clin Pathol; 2021 Jun; 156(1):155-165. PubMed ID: 33491064
[TBL] [Abstract][Full Text] [Related]
5. Clinic-Pathological Features of Breast Ductal Carcinoma
Zheng J; Zhou T; Li F; Shi J; Zhang L
Cancer Invest; 2020 Feb; 38(2):113-121. PubMed ID: 31939679
[No Abstract] [Full Text] [Related]
6. Risk of subsequent in situ and invasive breast cancer in human epidermal growth factor receptor 2-positive ductal carcinoma in situ.
Curigliano G; Disalvatore D; Esposito A; Pruneri G; Lazzeroni M; Guerrieri-Gonzaga A; Luini A; Orecchia R; Goldhirsch A; Rotmensz N; Bonanni B; Viale G
Ann Oncol; 2015 Apr; 26(4):682-687. PubMed ID: 25600567
[TBL] [Abstract][Full Text] [Related]
7. HER-2/neu overexpression as a predictor for the transition from in situ to invasive breast cancer.
Roses RE; Paulson EC; Sharma A; Schueller JE; Nisenbaum H; Weinstein S; Fox KR; Zhang PJ; Czerniecki BJ
Cancer Epidemiol Biomarkers Prev; 2009 May; 18(5):1386-9. PubMed ID: 19383888
[TBL] [Abstract][Full Text] [Related]
8. Biologic behavior and long-term outcomes of breast ductal carcinoma in situ with microinvasion.
Fang Y; Wu J; Wang W; Fei X; Zong Y; Chen X; Huang O; He J; Chen W; Li Y; Shen K; Zhu L
Oncotarget; 2016 Sep; 7(39):64182-64190. PubMed ID: 27577080
[TBL] [Abstract][Full Text] [Related]
9. The significance of HER-2/neu receptor positivity and immunophenotype in ductal carcinoma in situ with early invasive disease.
Harada S; Mick R; Roses RE; Graves H; Niu H; Sharma A; Schueller JE; Nisenbaum H; Czerniecki BJ; Zhang PJ
J Surg Oncol; 2011 Oct; 104(5):458-65. PubMed ID: 21557226
[TBL] [Abstract][Full Text] [Related]
10. Microinvasive breast carcinoma carries an excellent prognosis regardless of the tumor characteristics.
Shatat L; Gloyeske N; Madan R; O'Neil M; Tawfik O; Fan F
Hum Pathol; 2013 Dec; 44(12):2684-9. PubMed ID: 24071019
[TBL] [Abstract][Full Text] [Related]
11. Comparison of HER2 amplification status among breast cancer subgroups offers new insights in pathways of breast cancer progression.
Lambein K; Van Bockstal M; Vandemaele L; Van den Broecke R; Cocquyt V; Geenen S; Denys H; Libbrecht L
Virchows Arch; 2017 Nov; 471(5):575-587. PubMed ID: 28567637
[TBL] [Abstract][Full Text] [Related]
12. [Expression of fatty acid synthase and its association with HER2 in invasive ductal carcinoma of breast].
Yang M; Xu SP; Ao QL
Zhonghua Bing Li Xue Za Zhi; 2013 Apr; 42(4):257-61. PubMed ID: 23928534
[TBL] [Abstract][Full Text] [Related]
13. The clinical and biological significance of HER2 over-expression in breast ductal carcinoma in situ: a large study from a single institution.
Miligy IM; Toss MS; Gorringe KL; Lee AHS; Ellis IO; Green AR; Rakha EA
Br J Cancer; 2019 May; 120(11):1075-1082. PubMed ID: 31065110
[TBL] [Abstract][Full Text] [Related]
14. Application of a novel prognostic invasive lesion index in ductal carcinoma in situ with minimal invasion of the breast.
He X; Ye F; Li M; Yu P; Xiao X; Tang H; Xie X
Cancer Med; 2017 Nov; 6(11):2489-2496. PubMed ID: 28980458
[TBL] [Abstract][Full Text] [Related]
15. Clinicopathological Follow-up of Breast DCIS Diagnosed on Biopsies: A Single Institutional Study of 575 Patients.
Yan M; Bomeisl P; Gilmore H; Harbhajanka A
Int J Surg Pathol; 2021 Dec; 29(8):836-843. PubMed ID: 33890815
[TBL] [Abstract][Full Text] [Related]
16. Clonal alteration of breast cancer receptors between primary ductal carcinoma in situ (DCIS) and corresponding local events.
Karlsson E; Sandelin K; Appelgren J; Zhou W; Jirström K; Bergh J; Wärnberg F
Eur J Cancer; 2014 Feb; 50(3):517-24. PubMed ID: 24275214
[TBL] [Abstract][Full Text] [Related]
17. Is there a low-grade precursor pathway in breast cancer?
King TA; Sakr RA; Muhsen S; Andrade VP; Giri D; Van Zee KJ; Morrow M
Ann Surg Oncol; 2012 Apr; 19(4):1115-21. PubMed ID: 21935747
[TBL] [Abstract][Full Text] [Related]
18. Evaluating the Risk of Upstaging HER2-Positive DCIS to Invasive Breast Cancer.
Mustafa RE; DeStefano LM; Bahng J; Yoon-Flannery K; Fisher CS; Zhang PJ; Tchou J; Czerniecki BJ; De La Cruz LM
Ann Surg Oncol; 2017 Oct; 24(10):2999-3003. PubMed ID: 28766212
[TBL] [Abstract][Full Text] [Related]
19. Hormonal receptor status, Ki-67 and HER2 expression: Prognostic value in the recurrence of ductal carcinoma in situ of the breast?
Poulakaki N; Makris GM; Battista MJ; Böhm D; Petraki K; Bafaloukos D; Sergentanis TN; Siristatidis C; Chrelias C; Papantoniou N
Breast; 2016 Feb; 25():57-61. PubMed ID: 26612082
[TBL] [Abstract][Full Text] [Related]
20. Carcinoma in situ of the female breast. A clinico-pathological, immunohistological, and DNA ploidy study.
Ottesen GL
APMIS Suppl; 2003; (108):1-67. PubMed ID: 12874968
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]